These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Biotelemetric detection of the disappearance of subcutaneously injected 125I-NPH insulin. Kølendorf K; Bojsen J Clin Physiol; 1982 Feb; 2(1):13-20. PubMed ID: 7049511 [TBL] [Abstract][Full Text] [Related]
6. Clinical factors influencing the absorption of 125I-NPH insulin in diabetic patients. Kølendorf K; Bojsen J; Deckert T Horm Metab Res; 1983 Jun; 15(6):274-8. PubMed ID: 6409773 [TBL] [Abstract][Full Text] [Related]
7. Absorption of soluble and isophane semi-synthetic human and porcine insulin in insulin-dependent diabetic subjects. Pramming S; Lauritzen T; Thorsteinsson B; Johansen K; Binder C Acta Endocrinol (Copenh); 1984 Feb; 105(2):215-20. PubMed ID: 6364670 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes. Luzio SD; Beck P; Owens DR Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275 [TBL] [Abstract][Full Text] [Related]
9. Absorption kinetics of regular and isophane (NPH) insulin in the normal dog. Goeders LA; Esposito LA; Peterson ME Domest Anim Endocrinol; 1987 Jan; 4(1):43-50. PubMed ID: 3333933 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Owens DR; Coates PA; Luzio SD; Tinbergen JP; Kurzhals R Diabetes Care; 2000 Jun; 23(6):813-9. PubMed ID: 10841002 [TBL] [Abstract][Full Text] [Related]
11. The contribution of intermediate-acting insulin preparations to daytime insulin treatment. Robert JJ; Chevenne D; Debray M Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136 [TBL] [Abstract][Full Text] [Related]
12. Variation in 125I-insulin absorption and blood glucose concentration. Lauritzen T; Faber OK; Binder C Diabetologia; 1979 Nov; 17(5):291-5. PubMed ID: 499686 [TBL] [Abstract][Full Text] [Related]
13. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Thow JC; Johnson AB; Marsden S; Taylor R; Home PD Diabet Med; 1990 Nov; 7(9):795-9. PubMed ID: 2148131 [TBL] [Abstract][Full Text] [Related]
14. Effect of major surgery on absorption rate of NPH insulin injected s.c. Hjortrup A; Madsbad S; Andersen M; Sørensen C Br J Anaesth; 1990 Jun; 64(6):741-2. PubMed ID: 2378778 [TBL] [Abstract][Full Text] [Related]
15. Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats. Wallace MS; Peterson ME; Nichols CE Domest Anim Endocrinol; 1990 Oct; 7(4):509-15. PubMed ID: 2261761 [TBL] [Abstract][Full Text] [Related]
17. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Jørgensen KH; Hansen AK; Buschard K Diabetes Res Clin Pract; 2000 Dec; 50(3):161-7. PubMed ID: 11106830 [TBL] [Abstract][Full Text] [Related]
18. Study of porcine and human isophane (NPH) insulins in normal subjects. Owens DR; Jones IR; Birtwell AJ; Burge CT; Luzio S; Davies CJ; Heyburn P; Heding LG Diabetologia; 1984 Apr; 26(4):261-5. PubMed ID: 6376233 [TBL] [Abstract][Full Text] [Related]
19. Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site. Henriksen JE; Vaag A; Hansen IR; Lauritzen M; Djurhuus MS; Beck-Nielsen H Diabet Med; 1991 Jun; 8(5):453-7. PubMed ID: 1830531 [TBL] [Abstract][Full Text] [Related]
20. Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique. Thow JC; Johnson AB; Fulcher G; Home PD Diabet Med; 1990 Aug; 7(7):600-2. PubMed ID: 2146067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]